Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors.
Cell Proliferation
/ drug effects
Cell Survival
/ drug effects
Cells, Cultured
Dose-Response Relationship, Drug
Drug Design
Histone Deacetylase 6
/ antagonists & inhibitors
Histone Deacetylase Inhibitors
/ chemical synthesis
Humans
Imidazolidines
/ chemical synthesis
Molecular Structure
Structure-Activity Relationship
Anti-proliferative
Apoptosis
HDAC6 selective inhibitor
Structure optimization
Journal
European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510
Informations de publication
Date de publication:
05 Oct 2021
05 Oct 2021
Historique:
received:
30
03
2021
revised:
22
04
2021
accepted:
22
04
2021
pubmed:
17
5
2021
medline:
7
8
2021
entrez:
16
5
2021
Statut:
ppublish
Résumé
HDAC6 isoform selective inhibitors can be pursued as an alternative to pan-HDACs inhibitors due to their therapeutic effect and low toxicity. Efforts of the structure optimization of our previous compound 10c (IC
Identifiants
pubmed: 33992929
pii: S0223-5234(21)00375-5
doi: 10.1016/j.ejmech.2021.113526
pii:
doi:
Substances chimiques
Histone Deacetylase Inhibitors
0
Imidazolidines
0
HDAC6 protein, human
EC 3.5.1.98
Histone Deacetylase 6
EC 3.5.1.98
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
113526Informations de copyright
Copyright © 2021 Elsevier Masson SAS. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.